Table 2 Patients with Fanconi anaemia and AML treated by Allo-SCT
Patient | Pre-HSCT applied chemotherapy | Age at HSCT (years) | Remission at HSCT | Donor | HLA status, HLA typing | Graft and cell dose, CD34 in 10e6/kg MNC in 10e8/kg | Conditioning | GVHD prophylaxis | Engraftment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Low dose therapy: thioguanine 40 mg/m2/day, (8 days) cytarabine 40 mg/m2/day (7 days), single dose VCR 1.5 mg/m2/day | 8.8 | 0% Blasts in BM, Aplasia | Haplo | Haplo (father) | PBSC CD34: 30.10 (T-cell depleted) | Fludarabine 150 mg/m2, CY 20 mg/kg, ATG 80 mg/kg | OKT3, HD methylprednisolone | Yes | Alive (BO) (FU 174 months) |
2 | None | 14.11 | 32% Blasts in BM | MUD | Matched, 10/10 | BM MNC 2.13 | BU 1.6 mg/kg, fludarabine 180 mg/m2, ATG 60 mg/kg | CsA, OKT3, HD prednisolone | Yes | Alive (BO) (FU 75 months) |
3 | Low dose therapy: thioguanine 40 mg/m2/day(24 d) followed by 20 mg/m2/day (30 days), at the beginning cytarabine 40 mg/m2/day (4 days) | 10.9 | 0% Blasts in BM, Aplasia | MUD | Matched, 10/10 | BM MNC 3.43 | BU 1.6 mg/kg, fludarabine 180 mg/m2, CY 40 mg/kg, Alemtuzumab 35 mg/m2 | MMF, rapamycin | Yes | Alive (FU 14 months) |
